Targeting cancer with small molecule kinase inhibitors - Wikidata - wikimedia - TriplyDB

Targeting cancer with small molecule kinase inhibitors

Targeting cancer with small molecule kinase inhibitors

http://www.wikidata.org/entity/Q29547395

about

Recent developments of protein kinase inhibitors as potential AD therapeutics Identification of direct protein targets of small molecules Genome-wide association studies: how predictable is a person’s cancer risk?The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2 Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expression Mammalian target of rapamycin: a central node of complex signaling cascades Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles Clinical use of crizotinib for the treatment of non-small cell lung cancer Redox-directed cancer therapeutics: molecular mechanisms and opportunities Identifying druggable disease-modifying gene products Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach Chemical genetics approaches for selective intervention in epigenetics Current targeted therapies in the treatment of advanced colorectal cancer: a review Selective Sensing of Tyrosine Phosphorylation in Peptides Using Terbium(III) Complexes Drugging the undruggables: exploring the ubiquitin system for drug development Intracellular Delivery of Proteins with Cell-Penetrating Peptides for Therapeutic Uses in Human Disease Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors Chemical probes of histone lysine methyltransferases Small molecule compounds targeting miRNAs for cancer therapy Ten things you should know about protein kinases: IUPHAR Review 14 The dynamic nature of the kinome Markov state models provide insights into dynamic modulation of protein function Targeting cancer with kinase inhibitors The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance The next steps in next-gen sequencing of cancer genomes Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic The azaindole framework in the design of kinase inhibitors Targeting the adaptive molecular landscape of castration-resistant prostate cancer JNK signalling in cancer: in need of new, smarter therapeutic targets Implications of the small number of distinct ligand binding pockets in proteins for drug discovery, evolution and biochemical function Getting TRAIL back on track for cancer therapy Small-molecule inhibitors of myosin proteins Developing irreversible inhibitors of the protein kinase cysteinome

P2860

Q21129481-4870DACC-A117-44CD-A83A-5E45286C2A5B Q21558640-E533D719-B506-4288-B2F1-BF3DE7D8CD2A Q22241482-DE036528-6240-4618-BDE0-825CB9013286 Q24293505-EE28760D-1A0E-4055-AD51-751B2EBABBE8 Q24302043-321428AB-8365-4B4B-8FFF-190654BAB56C Q24321199-3A5D09B5-92CC-4F9E-94DF-CDC743232CF5 Q24601702-989440FA-CFF2-44B3-AE31-EAD40A9D317C Q24603213-21A5102D-AE63-4C88-B70B-CC38D77A7B26 Q24604831-A55BCCFE-8EF3-4068-81A8-E4B6964C5AB1 Q24614202-F2AD4E55-95B4-479D-A005-4896096A17F3 Q24630466-939F1B83-C568-4596-9BEB-092B5A356786 Q24645584-083EAAA4-3852-46EB-93A3-24E5B844B4F8 Q24646409-3E976EB3-F998-48BD-A82A-BAEA44498D1C Q24672143-A1EF6F3F-570D-4665-B5C1-A4585BCA7F30 Q26740037-E0771816-AF68-42AD-AC0E-42FB100B4FA1 Q26740067-D883157B-523E-496A-90D2-C56650520B54 Q26744839-D2B996E4-A274-4983-BAE9-CE681EEF12C8 Q26752823-4C6AC8A8-ED31-41B4-A068-7F2A279CBACB Q26767093-C6F3CC3E-AF5C-4784-8EC7-08ACA0DA5851 Q26769963-7B111526-3EAF-4E09-8E95-534699679866 Q26774478-1C99A2F7-D1A3-4CF7-A7BA-05483AF84BBB Q26774957-A9B30DA1-D08E-40CB-8DFC-435C5DFD81B4 Q26827580-19D39CCA-D9AD-4BAD-A2D2-419A3FF583A0 Q26829218-D3E83992-0921-46E1-AA58-C91F21586999 Q26829982-DF3DB58B-C807-4A77-8E48-69B86B45E94C Q26849417-FA5D4B85-1BAC-462C-9FDE-BF4804753838 Q26852588-F9FFF76E-4397-44FA-8BF5-582B26B684F8 Q26861597-FB04C1AE-57B0-4BBB-9059-BB11199D7F36 Q26865765-5E03CD66-B8DF-424C-AD22-CE9CCE69329B Q26866312-408EBD45-E736-42E3-8A13-C6B77B626178 Q26866517-500F1A9E-E83E-4A2A-BA94-C87782CE96C8 Q26998894-D7136005-9316-45FA-961A-27404D1086DD Q27007413-D6611A30-02E7-4CC4-8AD9-455287BD677D Q27013668-42C65004-5ACF-4280-8D09-91A232B52EF4 Q27022821-07598BB0-32F6-4806-90F2-3DB1192226E4 Q27023869-B972AD6E-3515-439F-A18E-7EF11951A334 Q27026364-6C7DBA85-C687-46CA-9A4E-C99E92FBFCAB Q27027460-376B2C9A-7B6A-4A6A-88AF-C30C3CBE9C32 Q27027635-9B7A4A91-4CAA-41D3-8CF1-D1A97040166C Q27027983-C062B15C-2C54-4F77-96D5-CBB5607DFA0A

P2860

Targeting cancer with small molecule kinase inhibitors

http://www.wikidata.org/entity/Q29547395

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Targeting cancer with small molecule kinase inhibitors

@ast

Targeting cancer with small molecule kinase inhibitors

@en

type

label

Targeting cancer with small molecule kinase inhibitors

@ast

Targeting cancer with small molecule kinase inhibitors

@en

prefLabel

Targeting cancer with small molecule kinase inhibitors

@ast

Targeting cancer with small molecule kinase inhibitors

@en

P1433

Q29547395-123B7CE9-616B-475F-B879-0013E984CBF1

P1476

Q29547395-58FF5FD2-5B03-4446-BE97-AB8CF3F79A81

P2093

Q29547395-41970063-20A4-41E4-A026-6344C35D9A31

Q29547395-44C2A643-10ED-4EC8-BFC1-E64C9A620D56

Q29547395-47699D26-D2F3-4A73-933E-1FCB8B30EBE7

P2860

Q29547395-04398222-3B43-48CC-903E-07198A3A9269

Q29547395-0C44D963-A47F-40F9-B2AC-3C64E7877C83

Q29547395-1C41EADC-173B-47F3-A842-2CA0B8BCD1CF

Q29547395-23021499-B93C-4868-8AF2-348495920587

Q29547395-2D4CB9DB-3CAD-4467-AB09-210383FCAF30

Q29547395-2DAF77FE-7351-4B79-ADAF-A3A55B7CCA05

Q29547395-3510339E-1083-41F3-8A1E-BFF2829DF9A4

Q29547395-36581C75-E879-49AA-B507-58A377C8E2CF

Q29547395-4015CF17-DE20-4A81-93E6-8D0005395E49

Q29547395-46E83230-0D80-4C25-AF33-A29FE1EF0986

P2888

Q29547395-74D5288F-4548-4171-8F0B-B3D588F94DBE

P304

Q29547395-C0A3C337-B85E-4D82-B04E-152A2F5480C4

P31

Q29547395-A85504B5-EF17-4875-81DB-0DFB73933A82

P3181

Q29547395-BC62C925-6860-4173-9A78-5BB4E602C920

P356

Q29547395-32E540ED-9976-479D-AB82-9D6B5F189035

P407

Q29547395-F26D3374-AA45-41A4-92BB-2013E7D40E0C

P433

Q29547395-4A62659C-7F9A-4020-8B12-FFB3815FD310

P478

Q29547395-4EAD48CC-0325-4785-B2DA-C1258C18FCD0

P577

Q29547395-0ADF5FF6-3F01-45BD-A91B-5FBBC0297450

P5875

Q29547395-627A98F4-1B1E-4357-AE50-812C575B3E13

P6179

Q29547395-71CF3CDA-FF24-4BED-936A-6871B37F846B

P698

Q29547395-F2744DEE-840B-419A-A53D-E7BE1FBBED55

P3181

P356

P1433

Nature Reviews Cancer

P1476

Targeting cancer with small molecule kinase inhibitors

@en

P2093

Gray NS

http://www.w3.org/2001/XMLSchema#string

Yang PL

http://www.w3.org/2001/XMLSchema#string

Zhang J

http://www.w3.org/2001/XMLSchema#string

P2860

The Sequence of the Human Genome

The protein kinase complement of the human genome

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

A census of human cancer genes

The selectivity of protein kinase inhibitors: a further update

Identification of ALK as a major familial neuroblastoma predisposition gene

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structural basis for the autoinhibition of c-Abl tyrosine kinase

Crystal structure of the T315I mutant of AbI kinase

P2888

P304

28-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

130617

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC2559

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23686085

http://www.w3.org/2001/XMLSchema#string

P6179

1001079875

http://www.w3.org/2001/XMLSchema#string

P698

19104514

http://www.w3.org/2001/XMLSchema#string